Chembio Diagnostics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Richard L. Eberly
- Full Time Employees
- 188
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 555 Wireless Boulevard Hauppauge NY United States of America 11788
- IPO Date
- Oct 18, 2000
- CIK
- 0001092662
- Website
- chembio.com
- Similar Companies
- Business
- Chembio Diagnostics, Inc. (CEMI) develops, manufactures, commercializes, and licenses rapid point-of-care diagnostic tests for infectious diseases, leveraging its proprietary Dual Path Platform (DPP) technology for multiplexed detection from small blood samples in 15 to 20 minutes; core products include DPP HIV 1/2 Assay, DPP HIV-Syphilis, DPP Syphilis Screen & Confirm, HIV 1/2 STAT PAK Assay, STAT-VIEW HIV 1/2 Assay, SURE CHECK HIV 1/2 and self-test kits, Chagas STAT PAK Assay, DPP Zika IgM/IgG and IgM Systems for tropical and fever diseases, and DPP Micro Reader for objective results, with veterinary diagnostics and respiratory disease tests also offered. The company, founded in 1985 and headquartered in Medford, New York, operates globally through direct sales and distributors to hospitals, clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers, with subsidiaries in Germany, Brazil, and Malaysia. Acquired in April 2023 by Biosynex SA for $0.45 per share in a $17.2 million transaction, Chembio now functions as a wholly-owned indirect subsidiary, delisted from Nasdaq, and benefiting from operational synergies in procurement, R&D, logistics, and production; recent developments include FDA CLIA Waiver for DPP HIV-Syphilis, FDA Breakthrough Device Designation for DPP Syphilis TnT Assay, a $1.5 million Bill & Melinda Gates Foundation grant in October 2024 for a DPP Congenital Syphilis Assay detecting Treponemal and Non-Treponemal IgM/IgA, and a grant for a rapid POC preeclampsia test.
Life Science Outsourcing, Inc. Welcomes Neil A. Goldman as Chief Financial Officer
10 Best-Performing Penny Stocks in the Health Care Sector
CHEMBIO DIAGNOSTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chembio Diagnostics, Inc. - CEMI
CEMI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chembio Diagnostics, Inc. Is Fair to Shareholders
Chembio Diagnostics, Inc. (CEMI) Q3 2022 Earnings Call Transcript
Chembio Diagnostics to Report Third Quarter 2022 Financial Results on November 3, 2022
Trending Penny Stocks For Your September Watchlist
Chembio Diagnostics, Inc.'s (CEMI) CEO Rick Eberly on Q2 2022 Results - Earnings Call Transcript
10 Top Monkeypox Stocks To Watch Right Now
Best Penny Stocks To Buy Now? 4 Monkeypox Stocks To Watch This Week
Chembio Diagnostics to Report Second Quarter 2022 Financial Results on August 4, 2022
Hot Penny Stocks For Your Buy List This Month? 3 to Watch
Chembio Diagnostics, Inc. (CEMI) CEO Rick Eberly on Q1 2022 Results - Earnings Call Transcript
Chembio Diagnostics to Report First Quarter 2022 Financial Results on May 5, 2022
Despite More Than Double Q4 Sales, Chembio Diagnostics Posts Deeper Losses
Why Chembio Diagnostics Shares Are Falling
Chembio Diagnostics, Inc. (CEMI) CEO Richard Eberly on Q4 2021 Results - Earnings Call Transcript
FDA Asks Chembio Additional Data On HIV-Syphilis Test For CLIA Waiver
3 Penny Stocks to Watch Under $4 Right Now
Chembio Diagnostics' DPP COVID-19 Antigen Test Approved In South Africa